Financial Performance - The company's revenue for Q1 2023 was ¥588,724,855.57, a decrease of 4.07% compared to ¥613,719,586.39 in the same period last year[3] - Net profit attributable to shareholders was ¥4,536,891.13, representing a significant increase of 108.34% from a loss of ¥54,380,193.73 in the previous year[3] - The net cash flow from operating activities improved to ¥54,977,540.05, a remarkable increase of 467.27% compared to a negative cash flow of ¥14,969,306.51 in the same period last year[3] - Basic earnings per share rose to ¥0.01, up 112.50% from a loss of ¥0.08 per share in the previous year[3] - Total operating revenue for Q1 2023 was CNY 588,724,855.57, a decrease of 4.8% compared to CNY 613,719,586.39 in the same period last year[18] - The company reported a net loss of CNY 495,579,610.22, slightly improved from a loss of CNY 500,116,501.35 in the previous year[16] - The net profit for Q1 2023 was ¥8,281,817.19, a significant recovery from a net loss of ¥41,900,248.37 in the same period last year, marking a turnaround of over 119%[19] - Operating profit reached ¥15,158,572.24, compared to an operating loss of ¥41,298,471.93 in Q1 2022, indicating a strong operational improvement[19] - The company reported a total comprehensive income of ¥3,899,115.34, recovering from a comprehensive loss of ¥42,054,654.04 in the same quarter last year[20] - Basic and diluted earnings per share were both ¥0.01, compared to a loss per share of ¥0.08 in Q1 2022, indicating a positive shift in profitability[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,320,480,655.95, a slight decrease of 0.35% from ¥9,353,000,538.98 at the end of the previous year[3] - Total liabilities decreased to CNY 6,498,399,773.40 from CNY 6,534,818,771.77, a decline of 0.56%[16] - The total equity increased marginally to CNY 2,822,080,882.55 from CNY 2,818,181,767.21, reflecting stability in shareholder value[16] Cash Flow and Investments - Cash and cash equivalents decreased to CNY 142,992,750.49 from CNY 166,503,309.05, a decline of 14.1%[15] - The cash flow from operating activities generated a net inflow of ¥54,977,540.05, a significant improvement from a net outflow of ¥14,969,306.51 in Q1 2022[21] - Investment activities resulted in a net cash outflow of ¥20,344,101.11, contrasting with a net inflow of ¥282,865,481.43 in Q1 2022, highlighting a shift in investment strategy[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 56,764[8] - The largest shareholder, Guangzhou Kunlun Investment Co., Ltd., holds 23.09% of shares, with 152,709,621 shares pledged and 16,987,024 shares frozen[8] - The top ten shareholders collectively hold significant stakes, with the second-largest shareholder holding 4.06%[8] - The company has a total of 3,890,503 restricted shares at the end of the reporting period, with no shares released during the current period[9] Legal Matters - The company is involved in multiple legal disputes, including a contract dispute with a total execution amount of 58,912,000 RMB and another for 122,555,968 RMB[11] - The company has reached a settlement in a previous dispute but is facing enforcement actions due to unpaid amounts[11] - The company is committed to normal production operations while monitoring the progress of legal matters[12] Operating Costs and Expenses - The company reported a 41.33% increase in taxes and surcharges, attributed to higher tax obligations during the reporting period[6] - The company experienced a 305.87% increase in operating expenses, primarily due to an increase in estimated liabilities[6] - Total operating costs decreased to CNY 587,997,301.38 from CNY 713,529,042.61, representing a reduction of 17.6%[18] - Research and development expenses increased to CNY 17,941,867.46, up from CNY 14,074,755.90, reflecting a focus on innovation[18] - The company incurred a total of ¥6,828,584.34 in non-operating expenses, which is a significant increase from ¥1,682,436.25 in the previous year, indicating higher costs in this area[19] Inventory and Cash Management - Inventory increased to CNY 507,634,706.79 from CNY 467,074,930.98, an increase of 8.6%[15] - The cash and cash equivalents at the end of the period stood at ¥85,772,717.82, down from ¥328,374,768.80 at the end of Q1 2022, reflecting a decrease of approximately 73.9%[23] - Financing activities led to a net cash outflow of ¥75,181,381.45, compared to a net outflow of ¥111,112,301.34 in the same quarter last year, indicating improved cash management in financing[23] Profitability and Cost Management - Gross profit margin improved to 0.12% from a negative margin in the previous year, indicating better cost management[18] - Non-recurring gains and losses totaled ¥1,436,883.89, primarily due to government subsidies and asset disposal gains[4]

Financial Performance - The company achieved operating revenue of CNY 2,187,069,901.40, a decrease of 26.38% year-on-year[23]. - The net profit attributable to shareholders was CNY -533,158,456.93, an increase of 22.56% compared to the previous year[23]. - The cash flow from operating activities was CNY 227,377,262.86, down 11.72% from the previous year[23]. - The total assets at the end of 2022 were CNY 9,353,000,538.98, a decrease of 17.82% from the end of 2021[23]. - The net assets attributable to shareholders decreased by 18.35% to CNY 2,405,133,051.46 compared to the end of 2021[23]. - The basic earnings per share were CNY -0.81, an improvement of 22.12% from CNY -1.04 in the previous year[23]. - The total amount of non-recurring gains and losses for 2022 was approximately $19.95 million, a decrease from $42.11 million in 2021[29]. - The company reported a significant reduction in soft drink sales, with a 93.7% decrease in sales volume and a 100% drop in production volume[65]. - The company reported a total revenue of 3.689 billion CNY for the year 2022, reflecting a significant performance in the pharmaceutical sector[132]. - The company reported a total of 16,520,000 CNY for expected daily related transactions in 2022, with actual transactions amounting to 5,793,240 CNY for goods sold and 1,029,870 CNY for leasing[194]. Business Strategy and Operations - The company continues to focus on its core business despite challenges from the macro environment and rising raw material prices[3]. - The company emphasizes that its core competitiveness and main business have not undergone significant adverse changes[3]. - The company is focused on the modernization and industrialization of traditional Chinese medicine, supported by government policies aimed at enhancing the sector's development[32]. - The company is engaged in the research and development of T-cell immunotherapy drugs, with ongoing projects targeting soft tissue sarcoma and primary liver cancer[35]. - The company has established a comprehensive supply chain management system for the procurement of traditional Chinese medicine materials, ensuring quality and stability in supply[36]. - The company has maintained a stable product line, including antiviral oral liquids and various traditional Chinese medicine products, with no significant changes reported during the period[35]. - The company aims to modernize traditional Chinese medicine and expand its industry chain, including establishing standardized processing bases and logistics[96]. - The company is focusing on precision medicine, collaborating with medical institutions to develop clinical research projects and treatment centers[96]. - The company plans to explore new medical service models, including telemedicine and smart healthcare, to integrate resources from traditional and Western medicine[96]. - The company will focus on its core business, optimizing resource allocation to enhance scale efficiency and improve market share in the cold and cough product segments[98]. Research and Development - Ongoing clinical trials include KX02 for malignant glioma and a high-affinity TCR cell therapy for soft tissue sarcoma, indicating active R&D efforts[43][44]. - The company has established a complete TCR-T technology platform, achieving international advanced levels in tumor immunotherapy[45]. - The company’s subsidiary, Xiangxue Life Sciences, has a TCR-T cell immunotherapy product, TAEST16001, which is currently in Phase II clinical trials[57]. - The total R&D investment as a percentage of operating income increased to 6.12% from 4.60% in 2021[76]. - The company is committed to enhancing its research and development capabilities to drive innovation in the pharmaceutical industry[135]. Governance and Compliance - The company has established a governance structure that includes a board of directors, supervisory board, and management team, ensuring compliance with relevant laws and regulations[113]. - The company emphasizes the importance of information disclosure, adhering to regulations to provide accurate and timely information to investors[119]. - The company maintains good communication with investors through various channels, including performance briefings and investor visits, to keep them informed about its strategic direction and business developments[120]. - The company has received a warning from the China Securities Regulatory Commission regarding non-compliance with disclosure obligations, which highlights the need for improved governance[135]. - The company has established a compensation committee to determine the remuneration of directors and senior management based on performance and responsibilities[139]. Legal and Regulatory Issues - The company faces multiple legal disputes, including a significant lawsuit involving 300 million yuan related to investment rights and another arbitration case involving approximately 280 million yuan, which could affect its financial standing[108][109]. - The company has pledged assets such as the Yunpu plant and the Biological Island No. 1 plot to cover the amounts involved in the lawsuits, indicating a proactive approach to managing legal risks[109]. - The company has been fined 250,000 yuan for violating advertising laws, but this is not expected to have a major impact on operations[190]. - The company is actively seeking reasonable solutions for ongoing litigation and has engaged a professional legal team to protect its rights[191]. Employee and Management - The total number of employees at the end of the reporting period was 2,417[150]. - The company has a comprehensive annual training plan focusing on employee development, covering various skills and management capabilities[152]. - The company has optimized its training system to enhance employee learning efficiency and engagement through internal resources and new technologies[152]. - The company has established a performance evaluation system for senior management, with the compensation committee responsible for determining annual remuneration based on operational performance and management indicators[161]. Environmental Responsibility - The company invested approximately 1.35 million yuan in wastewater treatment, environmental testing, and solid/hazardous waste management in 2022[174]. - The company has implemented a wastewater treatment facility with a design capacity of 360 m³/d, ensuring compliance with national standards[172]. - The company reported no major environmental penalties during the reporting period[174]. - The company actively promotes green practices and resource efficiency, reflecting its commitment to environmental responsibility[175].

广州市香雪制药股份有限公司（以下简称"公司"）于 2023 年 4 月 22 日在 巨潮资讯网披露 2022 年年度报告及其摘要。为了让广大投资者更加深入全面地 了解公司 2022 年度的经营情况，公司将于 2023 年 5 月 5 日（星期五）下午 15 ：00-17：00 在深圳证券交易所提供的"互动易"平台以网络远程的方式举办 2022 年度业绩说明会，投资者可登录"互动易"网站（http://irm.cninfo.com.cn ）进入"云访谈"栏目参与本次年度业绩说明会。 出席本次年度业绩说明会的人员有：公司董事长兼总经理王永辉先生、独立 董事吴杰先生、董事会秘书徐力先生、财务总监牛晓燕女士。 为充分尊重投资者、提升交流的针对性，现就公司本次年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可提前登录"互 动易"网站进入公司本次年度业绩说明会页面进行提问，公司将在年度业绩说明 会上对投资者关注的问题进行回答。欢迎广大投资者积极参与！ 特此公告。 证券代码:300147 证券简称: 香雪制药 公告编号:2023-019 广州市香雪制药股份有限公司 关于举行 2022 年度业绩网 ...

证券代码：300147 证券简称：香雪制药 编号：20140828 广州市香雪制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | | √特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ | 新闻发布会 □路演活动 | | | □现场参观 | □ 一对一沟通 | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 华泰证券股份有限公司：杨烨辉、罗毅； | | 人员姓名 | 南方基金管理有限公司：韩海峰 | | | 时间 | 2014-8-28 16:00 | 至 18:00 | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事会秘书：黄滨 | | | 员 | 副总经理：曾仑 | | | | 证券事务代表：徐力 | | | | 财务经理：卢锋 | | | ...

证券代码：300147 证券简称：香雪制药 编号：20150824 广州市香雪制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------|--------------------------------------------------| | | | | | 投资者关系活动 | | √特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | □ 一对一沟通 | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 银河证券 | | | 人员姓名 | 深圳市武当资产管理有限公司 | | | | 上海财通资产管理有限公司 | | | | 北京玺萌财富投资管理有限公司 | | | | 中国长城资产管理公司 | | | 时间 | 2015-8-24 | | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事会秘书：黄滨 | | | 员 | 财务总监：陈文进 | | | | 证券 ...

证券代码：300147 证券简称：香雪制药 编号：20150721 广州市香雪制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √特定对象调研 □分析师会议 | | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | □ 一对一沟通 | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 大成基金管理有限公司：阳来军 | | | 人员姓名 | 招商基金管理有限公司：赵伟 | | | | | 广发证券资产管理（广东）有限公司：孙隽勃、刘宁 | | 时间 | 2015-7-21 | | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事会秘书：黄滨 | | | 员 | 证券事务代表：徐力 | | | 投资者关系活动 | | （一）公司在中药 ...

证券代码：300147 证券简称：香雪制药 编号：20150513 | --- | --- | --- | |----------------|------------------------------|----------------------------------------| | | | | | 投资者关系活动 | √特定对象调研 □分析师会议 | | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | □ 一对一沟通 | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 深圳市创海富信资产管理有限公司：许均华 | | 人员姓名 | | 南山资本东海长基投资基金：李思婷 | | | | 创金合信基金管理有限公司：皮劲松 | | | | 上海兴聚投资管理有限公司：朱节 | | | | 诺安基金管理有限公司：罗春蕾，杜佐远 | | | | 深圳前海汇杰达理资本有限公司：解睿 | | | 易方达基金管理有限公司：郭杰 | | | | 天弘基金管理有限公司：郭相博 | | | | 华创证券有限责任公司：王昊 | ...

证券代码：300147 证券简称：香雪制药 编号：20151216 广州市香雪制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|----------------------------|----------------------------------------------| | | | | | 投资者关系活动 | | √特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ | 新闻发布会 □路演活动 | | | □现场参观 | □ 一对一沟通 | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | | 广发基金管理有限公司：刘晓龙、王瑞冬、郑超群 | | | | 农银汇理基金管理有限公司：徐治彪 | | | 招商基金管理有限公司：赵伟 | | | | 西南证券股份有限公司：陈进 | | | | | 深圳望正资产管理有限公司：王琦 | | | | 淡水泉（北京）投资管理有限公司：隋江波 | | | | 拾贝投资管理（北京）有限公司：张剑 | | 时间 | 2015-12-16 | ...

证券代码：300147 证券简称：香雪制药 编号：20141106 广州市香雪制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|--------------------------------|------------------------------------------| | | | | | 投资者关系活动 | √特定对象调研 □分析师会议 | | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | □ 一对一沟通 | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 中国中投证券有限责任公司：池陈森； | | 人员姓名 | | 广州广证恒生证券投资咨询有限公司：张伟； | | | 广东银石投资有限公司：谢成长； | | | | 招商证券股份有限公司：王准飞 | | | | 国信证券股份有限公司：邵燕芳； | | | | 大成基金管理有限公司：杨挺。 | | | 时间 | 2014-11-6 15:00 | 至 17:00 | | 地点 | 公 ...

Group 1: Company Development Strategy - The company focuses on the development of traditional Chinese medicine modernization as its strategic direction, emphasizing endogenous growth, external expansion, business model innovation, and leading-edge technology as four driving forces [3][4] - The company has competitive advantages in the development strategy, operational mechanism, management model, technology, and marketing aspects of the traditional Chinese medicine sector [3] Group 2: Clinical Research and Collaborations - The first phase of the clinical research project on specific T cell adoptive immunotherapy for solid tumors in collaboration with 458 hospitals has been completed, with the initial clinical summary report drafted [4] - The company is cautiously pursuing mergers and acquisitions as a path for external development, focusing on companies that complement its products, technology, and channels [4] Group 3: Employee Stock Ownership and Banking Progress - The first phase of the employee stock ownership plan is being implemented according to the asset management contract [5] - The establishment of Huacheng Bank is currently in the application process [5]